.
MergerLinks Header Logo

Announced

Completed

EcoR1 Capital-backed Panacea Acquisition completed the merger with Nuvation Bio in an $850m deal.

Financials

Edit Data
Transaction Value£650m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

biopharmaceuticals

Majority

United States

Acquisition

Reverse Takeover

Single Bidder

Biotechnology

Merger

Friendly

Domestic

Private Equity

Completed

De-SPAC

Synopsis

Edit

EcoR1 Capital-backed Panacea Acquisition, a special purpose acquisition company, completed the merger with Nuvation Bio, a biopharmaceutical company, in an $850m deal. "Our goal is to develop new generations of oncology medicines that will meaningfully improve patient lives by addressing drug resistance or limited efficacy of current therapies, while reducing side effects and preserving quality of life for cancer patients. The large financing that we will secure with this SPAC merger provides us with the capital we need to advance that goal," David Hung, Nuvation Bio Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US